Retatrutide vs Survodutide vs Mazdutide: Dual vs Triple Agonists Compared

Retatrutide, survodutide, and mazdutide belong to the same new wave of weight-loss drugs — the ones that add glucagon-receptor activation to the GLP-1 mechanism behind semaglutide — but they split into two camps. Survodutide (BI 456906) and mazdutide (IBI362) are GLP-1/glucagon dual agonists, while retatrutide (LY3437943) is a GLP-1/GIP/glucagon triple agonist. The question this comparison answers is whether that third receptor is worth it — and how three drugs at very different stages of approval and gray-market availability actually stack up.

The short version: on cross-trial numbers the triple agonist leads, mazdutide is the only one approved anywhere (in China), and retatrutide is by far the most independently tested if you are looking at the unregulated market. The longer version, below, separates what the trials actually compared from what the headlines imply. For where these sit among the broader field of weight-loss and metabolic peptides — and for the GLP-1 mono and GLP-1/GIP comparisons — the sections that follow put each in context.

What's the difference between a dual and a triple agonist?

A dual agonist activates two hormone receptors and a triple agonist activates three — and in this comparison the difference comes down to a single receptor: GIP. Survodutide and mazdutide are GLP-1/glucagon dual agonists, while retatrutide is a GLP-1/GIP/glucagon triple agonist. All three share glucagon-receptor activation, which raises energy expenditure and burns liver fat — the feature that separates this entire class from semaglutide and tirzepatide. Retatrutide adds a third receptor on top of that shared foundation.

One disambiguation matters before going further, because the word "dual" is used two different ways in this field. Tirzepatide is also called a dual agonist, but it targets GLP-1 and GIP with no glucagon activity. The duals in this article — survodutide and mazdutide — target GLP-1 and glucagon with no GIP. They are different two-receptor combinations, and the distinction is the whole point: tirzepatide and the GLP-1/glucagon duals reach similar weight-loss territory by different mechanistic routes. The taxonomy runs from one receptor to three: semaglutide (GLP-1 only), then tirzepatide (GLP-1/GIP) and survodutide/mazdutide (GLP-1/glucagon), then retatrutide (all three).

Each receptor contributes a distinct metabolic action, which is why combining them produces effects no single-receptor drug matches. The table below summarizes what activating each receptor does and which of the three compounds engages it.

Survodutide and mazdutide are both derived from or modeled on oxyntomodulin (OXM), a natural gut hormone that activates the GLP-1 and glucagon receptors — which is why both arrived at the same two-receptor design independently. Retatrutide is an engineered triple agonist rather than an OXM analog. The glucagon component is the shared thread: it is what lets all three reduce liver fat dramatically, and it is what distinguishes them from the GLP-1-only and GLP-1/GIP drugs already on the market.

How do their weight-loss results compare?

On the headline numbers, the triple agonist leads — retatrutide reported roughly 28% mean weight loss in its pivotal TRIUMPH-1 trial, versus up to about 20.1% for mazdutide at the 9 mg dose in GLORY-2 and 16.6% for survodutide in SYNCHRONIZE-1. But those figures come from separate trials in different populations, and mazdutide's were run in Chinese cohorts with a much lower starting BMI, which makes a clean ranking impossible. The numbers describe three drugs that all produce large, clinically meaningful weight loss; they do not establish that one is definitively stronger than another in the same patient.

The cross-trial problem is sharpest with mazdutide. Its GLORY trials enrolled participants with a mean BMI of roughly 31 kg/m² and a mean age around 34 years, whereas the Western trials of retatrutide and survodutide (and of semaglutide and tirzepatide) enrolled cohorts closer to 38 kg/m² and 45–47 years. Baseline BMI strongly influences the percentage of body weight a person can lose, so mazdutide's ~20% in a lower-BMI population is not directly comparable to retatrutide's ~28% in a higher-BMI one. Dose and trial duration differ too. This is exactly the kind of detail that headline comparisons omit and that changes how the numbers should be read.

Two evidence notes belong with this table. First, retatrutide's headline TRIUMPH-1 figure is a company topline announcement that has not yet been peer-reviewed and published, whereas its 24.2% Phase 2 result (Jastreboff et al., New England Journal of Medicine, 2023; n=338) is fully published. Mazdutide's GLORY-2 9 mg result is likewise topline, while GLORY-1 is published (Ji, Jiang et al., New England Journal of Medicine, 2025). Survodutide's SYNCHRONIZE-1 was published in NEJM in June 2026 (le Roux et al., New England Journal of Medicine, 2026). Second, the full trial-by-trial picture for the triple agonist — including which TRIUMPH trials have read out and which are pending — is covered in retatrutide's TRIUMPH trials.

Does adding the third receptor (GIP) actually help?

Adding GIP appears to help — retatrutide's weight-loss numbers run highest across the available trials — but "appears" is the operative word, because no study has directly compared a triple agonist against these GLP-1/glucagon duals. The third receptor is associated with greater efficacy across separate trials, yet GIP's precise contribution to weight loss remains debated even among researchers, partly because GIP-receptor agonism and antagonism have both been linked to weight benefits in different contexts. What is clearer is that the shared glucagon receptor, not GIP, drives the dramatic liver-fat reductions all three compounds produce. The mechanism behind retatrutide's design is explained further in how retatrutide's triple-agonist mechanism works.

The glucagon arm is where these three converge and where they collectively pull ahead of GLP-1-only drugs on metabolic markers beyond weight. Retatrutide's Phase 2 liver substudy showed liver fat falling by 82.4% at the top dose, with normal liver-fat content restored in 86% of participants; mazdutide's GLORY-1 reported roughly 80% liver-fat reduction; and survodutide is in dedicated Phase 2/3 development for metabolic dysfunction-associated steatohepatitis (MASH), where its glucagon-driven hepatic effect is the central rationale (Sanyal et al., New England Journal of Medicine, 2024). For a parallel comparison against the GLP-1 mono and GLP-1/GIP drugs, see retatrutide vs tirzepatide and semaglutide.

The practical takeaway is that "more receptors" is not automatically "better drug." A triple agonist offers the highest reported efficacy but engages more signaling pathways, which broadens the potential for both benefit and side effects. Until a head-to-head trial compares a triple agonist against a GLP-1/glucagon dual in the same population, the efficacy edge of the third receptor is a well-supported hypothesis rather than a settled fact.

How do their safety and tolerability profiles compare?

All three compounds share the gastrointestinal side-effect profile of the incretin class — nausea, vomiting, and diarrhea that are dose-dependent and concentrated during dose escalation — so on the common adverse events they look broadly similar. The clearest differentiator is retatrutide's dysesthesia signal, an abnormal and sometimes unpleasant skin sensation that emerged in its Phase 3 trials at the highest doses and has not been a defining feature of the dual agonists. Glucagon-receptor activation also warrants monitoring of heart rate and blood glucose across the whole class, since glucagon can raise both, an effect the GLP-1 component is designed to offset.

The dysesthesia finding is worth understanding rather than fearing. In retatrutide's trials it appeared at meaningful rates only at the higher doses, was generally mild, and is not the same as diabetic peripheral neuropathy. It is, however, a genuinely novel Phase 3 signal that the GLP-1/glucagon duals have not prominently shown, and it is one reason the triple agonist's tolerability profile is not simply "the duals plus more weight loss." A fuller dose-by-dose breakdown of retatrutide's adverse events appears in retatrutide's side effects, and the mechanism-and-safety profiles of the duals are covered in survodutide's mechanism and profile and mazdutide's mechanism and profile.

Where does each stand on approval and availability?

These three compounds sit at very different regulatory stages, which matters more than any efficacy gap for someone deciding what to do. As of June 2026, mazdutide is the only one approved anywhere — China's National Medical Products Administration (NMPA) cleared it for chronic weight management in June 2025 and for glycemic control in September 2025, making it the world's first GLP-1/glucagon dual agonist on any market. Retatrutide and survodutide remain investigational worldwide, with no approval from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

The development paths diverge from there. Eli Lilly has guided toward a U.S. regulatory submission for retatrutide around late 2026, which would put any approval and pharmacy availability after that review. Survodutide's pivotal SYNCHRONIZE-1 obesity trial was published in NEJM in June 2026 and its broader Phase 3 program is ongoing, but Boehringer Ingelheim has not yet secured approval in any market. Mazdutide is approved only in China; Eli Lilly holds the rights outside China and has not yet won approval elsewhere. The result is a field where one drug is prescribable in one country, and the other two are available legally nowhere. Regulatory status in this space changes quickly, so any specific claim should be re-checked at the time of reading; this reflects the position as of June 2026. For the practical legal question and the wider policy backdrop, see whether you need a prescription for retatrutide and the 2025–2026 FDA peptide-regulation timeline.

What does this mean for sourcing gray-market versions?

Outside China's mazdutide approval, none of these three compounds is legally available, so every consumer vial comes from the unregulated research-chemical market — and the amount of independent data to check a source against varies enormously by compound. Retatrutide is the single most-tested compound on Peptigrity's platform, with 624 independent HPLC purity tests at a 99.65% average across 219 shops (verified June 2026), out of more than 9,000 lab tests tracked across the independent lab-test database. Survodutide and mazdutide are far rarer in the gray market and carry far thinner verification coverage by comparison. Thin testing data is itself a sourcing risk, because there is less independent evidence to confirm what a given vendor is actually selling.

That asymmetry should shape expectations. With retatrutide, a buyer can cross-reference a vendor against hundreds of independent tests; with survodutide or mazdutide, the verification trail is sparse, which makes identity and dose far harder to confirm. Across all three, the same principle holds: chemical purity and actual quantity are separate questions, and a vial can be highly pure while containing materially more or less drug than its label claims. Verifying any source means confirming identity and purity (HPLC plus mass spectrometry) and checking stated milligrams against an independent assay — the methods are explained in how peptide testing works, and a compound-specific checklist of red flags is laid out in how to verify retatrutide before buying it. For translating a vial's concentration into a draw volume once verified, a retatrutide dosing calculator helps — though it is only as accurate as the vial's true contents.

Frequently Asked Questions

What's the difference between a dual and a triple agonist?

A dual agonist activates two hormone receptors and a triple agonist activates three. In this comparison, the GLP-1/glucagon dual agonists (survodutide and mazdutide) lack the GIP receptor that the triple agonist retatrutide adds. Note that tirzepatide is also called a "dual" agonist, but it targets GLP-1 and GIP rather than GLP-1 and glucagon, so it is a different two-receptor combination.

Which causes the most weight loss?

Across separate trials, retatrutide reports the highest mean weight loss (~28% in TRIUMPH-1), followed by mazdutide (up to ~20.1% at 9 mg) and survodutide (16.6%). But these come from different populations — mazdutide's trials used Chinese cohorts with much lower baseline BMI — so the ranking is suggestive rather than a controlled head-to-head result.

Is mazdutide approved?

Yes, in China. China's NMPA approved mazdutide for chronic weight management in June 2025, making it the world's first approved GLP-1/glucagon dual agonist. It is not approved by the FDA or EMA. Retatrutide and survodutide remain investigational worldwide as of June 2026.

Why add glucagon to a GLP-1 drug?

Glucagon-receptor activation raises energy expenditure and drives hepatic fat oxidation and lipolysis, on top of the appetite suppression and slowed gastric emptying that GLP-1 provides. That added pathway is why all three of these compounds produce large liver-fat reductions and distinguishes them from GLP-1-only drugs like semaglutide.

Are these the same as tirzepatide?

No. Tirzepatide is a GLP-1/GIP dual agonist with no glucagon activity. Retatrutide, survodutide, and mazdutide all activate the glucagon receptor — retatrutide as a triple agonist (adding GIP), and survodutide and mazdutide as GLP-1/glucagon duals.

Is gray-market survodutide or mazdutide as reliable as retatrutide?

No, in the sense that matters for verification. Retatrutide is the most independently tested compound on Peptigrity's platform, so a vendor can be checked against hundreds of HPLC results; survodutide and mazdutide are far less common in the gray market and have far thinner testing coverage, leaving less data to confirm a source's identity, purity, and dose.

This article is for educational and harm-reduction purposes only and does not constitute medical advice. Retatrutide and survodutide are investigational compounds not approved for human use by the FDA, EMA, MHRA, or other regulators as of June 2026; mazdutide is approved only in China. References to clinical-trial results describe research conducted with pharmaceutical-grade compound under medical supervision and do not imply safety or efficacy for unsupervised use of products obtained outside a regulated supply chain. Peptigrity is an independent review platform that does not sell peptides and has no financial relationship with any vendor. Consult a qualified healthcare professional before making any medical or health-related decision.